Keywords: pharmos, sells, 3m, common, stock, corp, discovery
Pharmos sells $4.3M of common stock
Article | 10 March 2003
Pharmos Corp, a US discovery, development and commercialization firmfocusing on novel therapeutics particularly for neurological and inflammation-based disorders, has raised $4.3 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
